Earnings summaries and quarterly performance for Viracta Therapeutics.
Research analysts covering Viracta Therapeutics.
Recent press releases and 8-K filings for VIRX.
Virion Therapeutics Reports Positive Phase 1b Study Results for VRON-0200
VIRX
New Projects/Investments
- VRON-0200, Virion Therapeutics' novel immunotherapy for HBV Functional Cure, was safe and well tolerated in its Phase 1b study, with no serious treatment-related adverse events.
- A single intramuscular dose of VRON-0200 induced sustained and/or continued HBsAg declines up to one year in 83% (19/23) of chronically HBV-infected patients.
- When combined with investigational antivirals, VRON-0200 produced rapid and profound HBsAg declines, with three of six patients achieving complete HBsAg loss by Week 20.
- The data supports the "Spark and Fan" model, positioning VRON-0200 as a potential foundational backbone agent for future HBV Functional Cure treatments, and a Phase 2b SPARK-B trial is in development.
Nov 9, 2025, 10:15 PM
Quarterly earnings call transcripts for Viracta Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more